Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to -$0.33.

  • Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) fell 322.22% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.43, marking a year-over-year decrease of 393.10%. This contributed to the annual value of -$0.33 for FY2024, which is 925.00% down from last year.
  • As of FY2024, Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.33, which was down 925.00% from $0.04 recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $0.58 in FY2021 and a low of -$0.33 during FY2024.
  • Over the past 3 years, Vanda Pharmaceuticals' median EPS (Weighted Average and Diluted) value was $0.04 (recorded in 2023), while the average stood at -$0.06.
  • In the last 5 years, Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 38.10% in 2021 and then tumbled by 925.00% in 2024.
  • Vanda Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at $0.42 in 2020, then skyrocketed by 38.10% to $0.58 in 2021, then crashed by 81.03% to $0.11 in 2022, then tumbled by 63.64% to $0.04 in 2023, then slumped by 925.00% to -$0.33 in 2024.